Polymer Technology Systems, Inc. Announces Over-The-Counter Clearance for Blood Ketone Test

Jan 03, 2000, 00:00 ET from Polymer Technology Systems, Inc.

    INDIANAPOLIS, Jan. 3 /PRNewswire/ -- Polymer Technology Systems, Inc., a
 privately held medical diagnostics manufacturer, announced they have received
 clearance from the Food and Drug Administration to market their blood ketone
 test to the consumer market. The test runs on the company's BioScanner
 2000(TM) analyzer and is designed for both home and physician office use.
     This brings the number of tests available for the BioScanner 2000(TM) in
 the over-the-counter market to three including glucose and total cholesterol.
     "Clearance of our blood ketone test is a significant step forward for PTS
 and the development of the BioScanner 2000," said Tracy Thompson, vice-
 president, business development. "Clearance of this tests means the BioScanner
 is the only system available to consumers and physicians capable of running
 glucose, cholesterol and ketones on the same instrument and takes advantage of
 the advanced optical properties of the system. This provides diabetics and
 heart patients the opportunity to utilize the same technology as their
 physicians in managing their disease."
     Ketones are produced in the body when insufficient insulin is available to
 metabolize glucose. As a result the body metabolizes fats and creates a state
 known as diabetic ketoacidosis (DKA), a condition that can be fatal.
 Previously ketones were measured in the urine using simple dipsticks, but this
 is a non-specific test and can lead to false negatives. The BioScanner test
 measures beta-hydroxybutyrate (BHBA) which is the predominant ketone type
 found in blood. The American Diabetes Association has published a position
 paper on ketones and recommends the testing of blood ketones over urine
     Polymer Technology Systems, Inc. develops and manufacturers products for
 the management of diabetes and its complications. Typical complications from
 diabetes include heart disease, peripheral vascular disease, blindness and
 kidney damage. Diabetes affects 16 million Americans and is managed through
 diet, medication and monitoring of blood parameters such as glucose,
 microalbumin, etc. In addition to the current portfolio of tests Polymer
 Technology Systems have direct LDL, microalbumin and hemoglobin A1c in
 development. Direct HDL-cholesterol and triglyceride tests are currently with
 the FDA awaiting consumer clearance.

SOURCE Polymer Technology Systems, Inc.